The advent of checkpoint inhibitors has altered the treatment landscape in urothelial bladder cancer, said Arlene O. Siefker-Radtke, MD, during last week’s NCCN Conference.
Rose McNulty
Advertisement
Articles by Rose McNulty
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Cigna Announces ‘Rebate-Free’ Pharmacy Benefit Model Starting in 2027
2
PBM Reform Debate: Panelists Clash Over Spread Pricing and Rebates | AMCP Nexus 2025
3
Rebates Play a Major Role in Whether Health Plans Restrict Access to Specialty Drugs | AMCP Nexus 2025
4
Not Red. Not Blue. Healthcare Is a Populist Issue, Says Costa | AMCP Nexus 2025
5
